- Home
- STBA vs COLL Comparison
STBA vs COLL Comparison
Compare STBA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STBA | COLL |
|---|---|---|
| Founded | 1902 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | STBA | COLL |
|---|---|---|
| Price | $43.60 | $47.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $42.20 | ★ $51.17 |
| AVG Volume (30 Days) | 191.1K | ★ 485.1K |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 2.27 | N/A |
| EPS | ★ 3.49 | 1.63 |
| Revenue | $394,697,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $9.61 | $26.17 |
| Revenue Next Year | $4.87 | $3.65 |
| P/E Ratio | ★ $12.60 | $29.64 |
| Revenue Growth | 2.85 | ★ 26.34 |
| 52 Week Low | $30.84 | $23.23 |
| 52 Week High | $44.27 | $50.79 |
Technical Indicators
Market Signals| Indicator | STBA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 52.94 |
| Support Level | $41.46 | $43.62 |
| Resistance Level | $42.51 | $46.94 |
| Average True Range (ATR) | 1.36 | 1.81 |
| MACD | 0.24 | 0.17 |
| Stochastic Oscillator | 79.87 | 65.58 |
Price Performance
Historical ComparisonAbout STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.